Krystal Biotech Inc (KRYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Krystal Biotech Inc (KRYS) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($80.38 Million) by net assets ($1.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Krystal Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
Krystal Biotech Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Krystal Biotech Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Krystal Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Krystal Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banca Transilvania S.A.
RO:TLV
|
0.028x |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
0.029x |
|
Empresas Copec S.A.
SN:COPEC
|
0.017x |
|
Plaza S.A
SN:MALLPLAZA
|
0.010x |
|
Autoliv Inc
NYSE:ALV
|
-0.029x |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
0.044x |
|
Agree Realty Corporation
NYSE:ADC
|
0.023x |
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
0.041x |
Annual Cash Flow Conversion Efficiency for Krystal Biotech Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Krystal Biotech Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Krystal Biotech Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.22 Billion | $200.87 Million | 0.165x | +26.29% |
| 2024-12-31 | $946.38 Million | $123.42 Million | 0.130x | +214.35% |
| 2023-12-31 | $778.64 Million | $-88.80 Million | -0.114x | +40.78% |
| 2022-12-31 | $522.23 Million | $-100.57 Million | -0.193x | -138.45% |
| 2021-12-31 | $593.58 Million | $-47.94 Million | -0.081x | +9.56% |
| 2020-12-31 | $292.08 Million | $-26.08 Million | -0.089x | +3.17% |
| 2019-12-31 | $202.91 Million | $-18.71 Million | -0.092x | -10.55% |
| 2018-12-31 | $113.23 Million | $-9.45 Million | -0.083x | -6.09% |
| 2017-12-31 | $49.47 Million | $-3.89 Million | -0.079x | +98.27% |
| 2016-12-31 | $289.00K | $-1.31 Million | -4.536x | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more